Abata in the News In Vivo Nonclinical Evaluation of Activity and Safety of a T Cell Receptor Engineered Regulatory T Cell Therapy for MS Progression Independent of Relapse Activity ECTRIMS 2024 Poster September 18, 2024 Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer Press Release September 16, 2024 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development Press Release August 15, 2024 Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis Press Release July 9, 2024 Harnessing regulatory T cells to establish immune tolerence Science Translational Medicine March 13, 2024 Preclinical Development of a T Cell Receptor Engineered Regulatory T Cell (Treg) Therapy for Progressive Pathology in MS ACTRIMS 2024 Poster February 29, 2024 Functional Characterization of Regulatory T cell (Treg) Therapy for the Treatment of Type 1 Diabetes (T1D) nPOD 2024 Poster February 19, 2024 Unveiling Novel T-cell Receptors (TCRs) for Enhanced Treg Cell Therapy in Type 1 Diabetes (T1D) nPOD 2024 Poster February 19, 2024 Are Cellular Therapies the Future of Autoimmune Disease? Medscape October 23, 2023 Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events Press Release August 28, 2023 Load More
